JAK
JAK (Janus kinase) inhibitors are compounds that target the JAK-STAT signaling pathway, which is involved in cell growth, immune response, and angiogenesis. By inhibiting JAK, these compounds can reduce the signaling that leads to the formation of new blood vessels in tumors, thereby inhibiting tumor growth. JAK inhibitors are important in the treatment of cancers and inflammatory diseases. At CymitQuimica, we offer a diverse range of high-quality JAK inhibitors to support your research in oncology, immunology, and angiogenesis.
Products of "JAK"
Sort by
JANEX-1
CAS:JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.Formula:C16H15N3O3Purity:98% - 99.73%Color and Shape:SolidMolecular weight:297.31Ref: TM-T2045
1mg44.00€2mg55.00€5mg92.00€10mg150.00€25mg248.00€50mg444.00€100mg652.00€500mg1,378.00€1mL*10mM (DMSO)92.00€MM-589
CAS:MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Formula:C28H44N8O5Purity:98%Color and Shape:SolidMolecular weight:572.70Povorcitinib phosphate
CAS:Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.Formula:C23H25F5N7O5PPurity:97.71%Color and Shape:SolidMolecular weight:605.45Ref: TM-T39113L
1mg65.00€2mg95.00€5mg145.00€10mg212.00€25mg359.00€50mg512.00€100mg695.00€200mg937.00€JAK-IN-33
JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].Purity:98%Color and Shape:Odour SolidPeficitinib
CAS:Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.Formula:C18H22N4O2Purity:98.67% - 99.4%Color and Shape:SolidMolecular weight:326.39Ref: TM-T6933
2mg40.00€5mg66.00€10mg104.00€25mg182.00€50mg283.00€100mg439.00€200mg645.00€1mL*10mM (DMSO)73.00€FLLL32
CAS:FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).Formula:C28H32O6Purity:96.39% - 97.90%Color and Shape:SolidMolecular weight:464.55Ref: TM-T6838
2mg46.00€5mg66.00€10mg93.00€25mg124.00€50mg197.00€100mg350.00€500mg840.00€1mL*10mM (DMSO)72.00€Cerdulatinib hydrochloride
CAS:Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.Formula:C20H28ClN7O3SPurity:99.23%Color and Shape:SolidMolecular weight:482Ifidancitinib
CAS:Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.Formula:C20H18FN5O3Purity:98.05%Color and Shape:SolidMolecular weight:395.39JAK-IN-10
CAS:JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.Formula:C20H18FN5O3SPurity:98.88%Color and Shape:SolidMolecular weight:427.45Ref: TM-T13571
1mg87.00€5mg177.00€10mg260.00€25mg429.00€50mg605.00€100mg815.00€500mg1,624.00€1mL*10mM (DMSO)188.00€Cerdulatinib
CAS:Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.Formula:C20H27N7O3SPurity:98.74% - 99.49%Color and Shape:SolidMolecular weight:445.54Ref: TM-T2487
1mg44.00€2mg55.00€5mg79.00€10mg106.00€25mg185.00€50mg283.00€100mg432.00€200mg605.00€500mg938.00€1mL*10mM (DMSO)86.00€Tofacitinib Citrate
CAS:Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).Formula:C22H28N6O8Purity:99.19% - 99.75%Color and Shape:SolidMolecular weight:504.49TAK-901
CAS:TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among othersFormula:C28H32N4O3SPurity:97.38% - 99.1%Color and Shape:SolidMolecular weight:504.64Brevilin A
CAS:Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.Formula:C20H26O5Purity:100% - 99.74%Color and Shape:SolidMolecular weight:346.42Ref: TM-T4672
1mg96.00€5mg215.00€10mg369.00€25mg610.00€50mg840.00€100mg1,130.00€500mg2,308.00€1mL*10mM (DMSO)235.00€Ilginatinib hydrochloride
CAS:Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.Formula:C21H21ClFN7Purity:99.55%Color and Shape:SolidMolecular weight:425.89Ref: TM-T12266L2
1mg77.00€5mg165.00€10mg240.00€25mg408.00€50mg562.00€100mg800.00€200mg1,074.00€1mL*10mM (DMSO)177.00€2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.Formula:C16H13Cl2N3O2Purity:98.77%Color and Shape:SolidMolecular weight:350.2JAK-IN-5 hydrochloride
CAS:JAK-IN-5 hydrochloride is a JAK inhibitor [1].Formula:C27H32ClFN6OColor and Shape:SolidMolecular weight:511.03JAK3-IN-6
CAS:JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nMFormula:C19H18N4O3Purity:97.46% - 99.94%Color and Shape:SolidMolecular weight:350.37Cenacitinib
CAS:Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Formula:C19H19F2N7O3Color and Shape:SolidMolecular weight:431.40JAK/HDAC-IN-2
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.Formula:C28H38N6O5SPurity:98%Color and Shape:SolidMolecular weight:570.7Nimucitinib
CAS:Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.Formula:C25H26F2N6O2Purity:98.71%Color and Shape:SoildMolecular weight:480.51Ref: TM-T67907
1mg96.00€2mg139.00€5mg227.00€10mg354.00€25mg653.00€50mg938.00€100mg1,454.00€500mg2,822.00€
